Hospira sees profits fall 73%

Hospira ($HSP), which makes pharma products and medical devices, saw its first-quarter net income drop sharply to $40.2 million, down from $149.9 million a year earlier. Quality issues and generic competition were cited as reasons for the decline. Still, company executives expressed optimism for the coming quarters. "Hospira delivered first-quarter results in line with our expectations, which reflects a difficult year-over-year comparison and the impact of our quality improvement initiatives," said CEO F. Michael Ball. Hospira release | Story

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.